JP2004519418A5 - - Google Patents

Download PDF

Info

Publication number
JP2004519418A5
JP2004519418A5 JP2002511766A JP2002511766A JP2004519418A5 JP 2004519418 A5 JP2004519418 A5 JP 2004519418A5 JP 2002511766 A JP2002511766 A JP 2002511766A JP 2002511766 A JP2002511766 A JP 2002511766A JP 2004519418 A5 JP2004519418 A5 JP 2004519418A5
Authority
JP
Japan
Prior art keywords
thyroid hormone
composition
compound
concentration
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002511766A
Other languages
English (en)
Other versions
JP2004519418A (ja
Filing date
Publication date
Priority claimed from US09/617,052 external-priority patent/US6380255B1/en
Application filed filed Critical
Publication of JP2004519418A publication Critical patent/JP2004519418A/ja
Publication of JP2004519418A5 publication Critical patent/JP2004519418A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】
患者の皮膚の皮膚病学手術における前処置のための組成物であって、
該組成物が少なくとも1つの甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物を局所塗布に適した薬理学的に許容可能な基剤と一緒に含み、該甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物が5×10−6M未満の平衡解離定数KでTR−αまたはTR−βと結合し、
=(R)・(L)/(RL)
(式中、(R)は受容体の濃度であり、(L)はリガンドの濃度であり、(RL)は受容体−リガンド複合体の濃度)
である組成物。
【請求項2】
患者の皮膚の易打撲傷性を減少させるための組成物であって、
該組成物が少なくとも1つの甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物を局所塗布に適した薬理学的に許容可能な基剤と一緒に含み、該甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物が5×10−6M未満の平衡解離定数KでTR−αまたはTR−βと結合し、
=(R)・(L)/(RL)
(式中、(R)は受容体の濃度であり、(L)はリガンドの濃度であり、(RL)は受容体−リガンド複合体の濃度)
である組成物。
【請求項3】
患者の真皮の細胞充実性及び厚みを増大させるための組成物であって、
該組成物が少なくとも1つの甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物を局所塗布に適した薬理学的に許容可能な基剤と一緒に含み、該甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物が5×10−6M未満の平衡解離定数KでTR−αまたはTR−βと結合し、
=(R)・(L)/(RL)
(式中、(R)は受容体の濃度であり、(L)はリガンドの濃度であり、(RL)は受容体−リガンド複合体の濃度)
である組成物。
【請求項4】
甲状腺ホルモン様アゴニスト化合物が、[4−(4−ヒドロキシ−3−ヨードフェノキシ)−3,5−ジヨードフェニル]酢酸(トリアック)又はその薬学的に許容される塩である請求項1〜3のいずれかに記載の組成物。
【請求項5】
前記薬理学的に許容可能な基剤が、リノール、オレイン、およびパルミチンからなる群から選択される1つまたはそれ以上の脂肪酸、エステルまたはトリグリセリド、およびリノレン脂肪酸、エステルまたはトリグリセリドを含む請求項1〜4のいずれかに記載の組成物。
【請求項6】
前記少なくとも1つの甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物が、組成物100ml当たり、500mg未満である請求項1〜5のいずれかに記載の組成物。
【請求項7】
前記少なくとも1つの甲状腺ホルモン化合物または甲状腺ホルモン様アゴニスト化合物が、組成物100ml当たり、200mg未満である請求項1〜6のいずれかに記載の組成物。
【請求項8】
患者が多因子性真皮萎縮を有する患者である請求項1〜7のいずれかに記載の組成物。
JP2002511766A 2000-07-14 2001-07-16 甲状腺ホルモンまたは甲状腺ホルモン様アゴニスト化合物 Pending JP2004519418A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/617,052 US6380255B1 (en) 1995-06-07 2000-07-14 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
PCT/GB2001/003182 WO2002005834A2 (en) 2000-07-14 2001-07-16 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012049349A Division JP2012144544A (ja) 2000-07-14 2012-03-06 甲状腺ホルモンまたは甲状腺ホルモン様アゴニスト化合物

Publications (2)

Publication Number Publication Date
JP2004519418A JP2004519418A (ja) 2004-07-02
JP2004519418A5 true JP2004519418A5 (ja) 2008-10-02

Family

ID=24472066

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002511766A Pending JP2004519418A (ja) 2000-07-14 2001-07-16 甲状腺ホルモンまたは甲状腺ホルモン様アゴニスト化合物
JP2012049349A Pending JP2012144544A (ja) 2000-07-14 2012-03-06 甲状腺ホルモンまたは甲状腺ホルモン様アゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012049349A Pending JP2012144544A (ja) 2000-07-14 2012-03-06 甲状腺ホルモンまたは甲状腺ホルモン様アゴニスト化合物

Country Status (6)

Country Link
US (2) US6380255B1 (ja)
EP (1) EP1328265A2 (ja)
JP (2) JP2004519418A (ja)
AU (1) AU2001270831A1 (ja)
CA (1) CA2415285A1 (ja)
WO (1) WO2002005834A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100405285B1 (ko) 1996-08-20 2003-11-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 합성 티로이드 호르몬을 포함하는 약제 조성물
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
GB0111314D0 (en) * 2001-05-09 2001-07-04 Karobio Ab Dermatological formulations
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
WO2005051298A2 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7919533B2 (en) * 2004-10-20 2011-04-05 Sal Abraham Diiodothyroacetic acid and method of use
CA2606498C (en) * 2005-05-26 2016-08-09 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
WO2007059039A1 (en) * 2005-11-11 2007-05-24 Oregon Health & Science University Thyroxine derivatives for preconditioning against stroke
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8179265B2 (en) 2006-06-21 2012-05-15 Neology, Inc. Systems and methods for breakaway RFID tags
US20090131380A1 (en) * 2007-11-16 2009-05-21 Pekka Heino Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515812A (ja)
GB782745A (en) 1953-08-13 1957-09-11 Arthur Alfred Hellbaum Improvements in or relating to pharmaceutical compositions
GB859546A (en) 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3090724A (en) * 1961-01-03 1963-05-21 Baxter Laboratories Inc Method of treating dermatological conditions
FR6435M (ja) * 1967-02-24 1968-11-04
FR6656M (ja) * 1967-02-23 1969-01-27
FR2139748B1 (ja) 1971-06-03 1974-08-30 Theranol Lab
FR2153202A1 (en) 1971-09-24 1973-05-04 Ind Chimique Triiodothyroacetic acid salts prepn - with metals and organic bases
CH622703A5 (en) 1976-06-10 1981-04-30 Berema Sa Therapeutic compositions for treating deposits of excess fat and infiltrates causing cellulite
FR2357246A1 (fr) 1976-07-09 1978-02-03 Martinez Gerard Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique
CH642851A5 (en) 1980-02-13 1984-05-15 Berema Sa Medicinal compositions for the treatment of cellulite
FR2501505A1 (fr) 1981-03-11 1982-09-17 Ana Laboratoires Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique
US4889847A (en) 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
US5118707A (en) 1990-10-31 1992-06-02 The Procter & Gamble Company Compositions for regulating skin wrinkles comprising a benzofuran derivative
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1993010755A1 (en) 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
DE69630380T8 (de) * 1995-06-07 2009-08-06 Lavin, Thomas N., Dr. Neue verwendungen von thyroidhormonen oder thyroidhormon aehnliche verbindungen
US5951989A (en) * 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands

Similar Documents

Publication Publication Date Title
JP2004519418A5 (ja)
EP1702597A3 (en) Drug delivery of phase changing formulation
JP2003501361A5 (ja)
EP1803443A3 (en) A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC)
JP2003509401A5 (ja)
WO2005107812A1 (en) Permeation enhancing compositions for anticholinergic agents
JP2002527727A5 (ja)
JP2002523446A (ja) 過活動性膀胱の治療のための抗ムスカリン剤としての経皮投与トルテロジン
JP2006265253A (ja) シリコーン中水型エマルション組成物
PT1612208E (pt) Composto de n-fenilarilsulfonamida, composição farmacêutica compreendendo o composto como ingrediente activo, intermediários de síntese para o composto e processos para a sua preparação
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
JP2740465B2 (ja) 経皮投与のための新規薬理投与形態
JP2000509037A (ja) 鎮咳剤として経皮投与されるデキストロメトルファン
EP1790346A3 (en) Use of bile acid or bile salt fatty acid conjugates
Fuhrman Jr et al. Effect of novel penetration enhancers on the transdermal delivery of hydrocortisone: an in vitro species comparison
WO2004112838A3 (en) Codrugs of diclofenac
JP2004513079A5 (ja)
Krahn et al. Examining serotonin function: a modified technique for rapid tryptophan depletion
Malhotra et al. Barnidipine
JP2005535635A5 (ja)
EP1269991A3 (en) Composition for topical use based on the ethylic ester of linoleic acid and on the triethyl ester of citric acid associated with suitable synergists
JPH02207024A (ja) 経皮吸収製剤
JP3086288B2 (ja) 経皮吸収製剤
WO2002044130A1 (fr) Dérivés d'acide carboxylique substitués
JP2002514404A5 (ja)